Who are we?
The understanding of the mechanisms of pain has significantly improved in the recent decade, but therapeutic innovation has not yet advanced. Morphine and opiate derivatives are still the privileged drugs used despite their negative side effects. Scientists have studied morphine’s mechanism of action and have separated the antalgic and the side effect, discovering a new target, TREK1 Channel, and developing a NCE specific of this target. This impacting discovery was published in Nature in 2013 after securing 2 patents. Innopain has exclusive worldwide license of these 2 patents and our mission is to develop non-opioid original analgesics to replace morphine without its side effects. Our objective is to get the proof of concept with clinical phase II- intravenous and oral, for acute and chronic pain.